Article

Daily Medication Pearl: Maralixibat (Livmarli)

Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Medication Pearl of the Day: Maralixibat (Livmarli)

Indication: Maralixibat (Livmarli) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Insight:

  • Dosing:The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day.
  • Dosage forms: Oral solution 9.5 mg of maralixibat per mL.
  • Adverse events: Most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
  • Mechanism of action: Maralixibat is a reversible inhibitor of IBAT. It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
  • Manufacturer: Mirum Pharmaceuticals

Source

prescribinginformation.pdf (mirumpharma.com)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com